PAM
REGN icon

Pamalican Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Pamalican Asset Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-6,900
Closed -$4.92M – 30
2024
Q4 		$4.92M Buy
+6,900
New +$5.79M 2.17% 16

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Pamalican Asset Management's REGN Position: Q1 2025 in Review

Pamalican Asset Management sold out of Regeneron Pharmaceuticals (REGN) in Q1 2025, closing a stake of 6,900 shares — an estimated $4.92M sold.

Pamalican Asset Management first reported a position in REGN in Q4 2024 and held it in 1 quarter. The position peaked at $4.92M in Q4 2024. 1,292 funds tracked by Wall St. Rank hold REGN as of Q1 2025.

  • Pamalican Asset Management reported no remaining Regeneron Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Pamalican Asset Management sold 6,900 Regeneron Pharmaceuticals shares in Q1 2025, an estimated $4.92M.
  • Pamalican Asset Management first reported a position in Regeneron Pharmaceuticals in Q4 2024 and held it in 1 quarter.
  • Pamalican Asset Management's Regeneron Pharmaceuticals position peaked at $4.92M in Q4 2024.
  • 1,292 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2025.

Based on Pamalican Asset Management's 13F filing for Q1 2025, filed 9 May 2025.